CACrown ArchivesThe cinema collection
Menu
Research dossier · General Reference

COPP (chemotherapy)

chemotherapy regimen for treatment of non-Hodgkin lymphoma

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionJun 10, 2025
Entity authorityQ1024110 ↗
Source-derived summary

COPP is a chemotherapy regimen for treatment of Hodgkin lymphoma, consisting of concurrent treatment with Cyclophosphamide, Oncovin, Procarbazine and Prednisone.

Compared with the similar MOPP regimen for both pediatric and adult cases, COPP uses less procarbazine (it is given only for 10 days in cycle instead of 14), and it replaces the very toxic mechlorethamine with cyclophosphamide, which is safer for progenitor stem cells (and hence less prone to causing severe neutropenia) and carries a lower risk of secondary malignancies.

Thus the COPP regimen is considered safer and less toxic than MOPP. But the benefits are offset by its lower efficacy, especially in advanced-stage Hodgkin lymphoma.

Editorial summary

This brief starts where responsible research should: with the source description of “COPP (chemotherapy)” as chemotherapy regimen for treatment of non-Hodgkin lymphoma. Everything that follows is an evidence route, not borrowed authority.

Editorial reviewA dependable orientation record for establishing vocabulary, names and a first evidence trail. The current 106-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. The account is most persuasive where COPP, chemotherapy and regimen can be independently traced.
Editorial analysis

Why this record matters

The subject matters to the general reference register because the source frames it as chemotherapy regimen for treatment of non-Hodgkin lymphoma. Its deeper value depends on whether names, dates, institutions and citations support that framing.

Evidence profile

Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jun 10, 2025. The linked authority identifier is Q1024110. None of the 0 selected statements returned an explicit reference.

Critical limits

A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “COPP (chemotherapy)”, its source revision and the description used here.
  2. Expand the search: follow COPP (chemotherapy) primary sources, COPP (chemotherapy) archive and COPP research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “COPP (chemotherapy)”?
  2. Which cited source is closest to the event, object or claim?
  3. What terminology or title could unlock a more precise catalogue search?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “COPP (chemotherapy)” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.